142 related articles for article (PubMed ID: 26142140)
1. Adherence to oral anticancer chemotherapy: What influences patients' over or non-adherence? Analysis of the OCTO study through quantitative-qualitative methods.
Bourmaud A; Henin E; Tinquaut F; Regnier V; Hamant C; Colomban O; You B; Ranchon F; Guitton J; Girard P; Freyer G; Tod M; Rioufol C; Trillet-Lenoir V; Chauvin F
BMC Res Notes; 2015 Jul; 8():291. PubMed ID: 26142140
[TBL] [Abstract][Full Text] [Related]
2. Over-adherence to capecitabine: a potential safety issue in breast and colorectal cancer patients.
Le Saux O; Bourmaud A; Rioufol C; Colomban O; Guitton J; Schwiertz V; Regnier V; You B; Ranchon F; Maraval-Gaget R; Girard P; Chauvin F; Freyer G; Tod M; Henin E; Trillet-Lenoir V
Cancer Chemother Pharmacol; 2018 Aug; 82(2):319-327. PubMed ID: 29948022
[TBL] [Abstract][Full Text] [Related]
3. [Validation of a questionnaire assessing patients' adherence and skill level of management for oral capecitabine treatment].
Baudot A; Oriol M; Tinquaut F; Moine V; Moriceau G; Muron T; Pacaut C; Collard O; Jacquin JP; Saban-Roche L; Bosacki C; Regnier-Denois V; Chauvin F; Bourmaud A
Bull Cancer; 2016 Mar; 103(3):241-51. PubMed ID: 26917467
[TBL] [Abstract][Full Text] [Related]
4. Low-dose capecitabine adjuvant chemotherapy in elderly stage II/III colorectal cancer patients (LC-ACEC): study protocol for a randomized controlled trial.
He Y; Liu P; Zhang Y; Deng X; Meng W; Wei M; Yang T; Wang Z; Qiu M
Trials; 2015 May; 16():238. PubMed ID: 26021722
[TBL] [Abstract][Full Text] [Related]
5. The Effect of Telephone-Based Follow-Up on Adherence, Efficacy, and Toxicity of Oral Capecitabine-Based Chemotherapy.
Eldeib HK; Abbassi MM; Hussein MM; Salem SE; Sabry NA
Telemed J E Health; 2019 Jun; 25(6):462-470. PubMed ID: 30048216
[No Abstract] [Full Text] [Related]
6. Adherence with oral oncologic treatment in cancer patients: interest of an adherence score of all dosing errors.
Thivat E; Van Praagh I; Belliere A; Mouret-Reynier MA; Kwiatkowski F; Durando X; Mahammedi H; Dillies AF; Chollet P; Chevrier R
Oncology; 2013; 84(2):67-74. PubMed ID: 23128040
[TBL] [Abstract][Full Text] [Related]
7. Clinical features of oral chemotherapy: results of a longitudinal prospective study of breast and colorectal cancer patients receiving capecitabine in the UK.
Brearley SG; Craven O; Saunders M; Swindell R; Molassiotis A
Eur J Cancer Care (Engl); 2010 Jul; 19(4):425-33. PubMed ID: 19708942
[TBL] [Abstract][Full Text] [Related]
8. Adherence and safety study in patients on treatment with capecitabine.
Fernández-Ribeiro F; Olivera-Fernández R; Crespo-Diz C
Farm Hosp; 2017 Mar; 41(2):204-221. PubMed ID: 28236798
[TBL] [Abstract][Full Text] [Related]
9. Association of serum folate level with toxicity of capecitabine in patients with colorectal cancers: a prospective cohort study.
Chan SL; Ma BB; Chan AK
Hong Kong Med J; 2018 Jun; 24 Suppl 3(3):29-31. PubMed ID: 29937443
[No Abstract] [Full Text] [Related]
10. Patient perspectives on the barriers associated with medication adherence to oral chemotherapy.
Muluneh B; Deal A; Alexander MD; Keisler MD; Markey JM; Neal JM; Bernard S; Valgus J; Dressler LG
J Oncol Pharm Pract; 2018 Mar; 24(2):98-109. PubMed ID: 27895220
[TBL] [Abstract][Full Text] [Related]
11. Adherence with oral chemotherapy: results from a qualitative study of the behaviour and representations of patients and oncologists.
Regnier Denois V; Poirson J; Nourissat A; Jacquin JP; Guastalla JP; Chauvin F
Eur J Cancer Care (Engl); 2011 Jul; 20(4):520-7. PubMed ID: 20649809
[TBL] [Abstract][Full Text] [Related]
12. Safety profile and activity of lower capecitabine dose in patients with metastatic breast cancer.
Rossi D; Alessandroni P; Catalano V; Giordani P; Fedeli SL; Fedeli A; Baldelli AM; Casadei V; Ceccolini M; Catalano G
Clin Breast Cancer; 2007 Dec; 7(11):857-60. PubMed ID: 18269775
[TBL] [Abstract][Full Text] [Related]
13. Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect?
Seminara P; Losanno T; Emiliani A; Manna G
Cardiology; 2010; 116(1):42-4. PubMed ID: 20431291
[TBL] [Abstract][Full Text] [Related]
14. Capecitabine-induced hypertriglyceridemia: a report of two cases.
Koutras AK; Habeos IG; Vagenakis AG; Kalofonos HP
Anticancer Res; 2006; 26(3B):2249-51. PubMed ID: 16821596
[TBL] [Abstract][Full Text] [Related]
15. Capecitabine in the routine first-line treatment of elderly patients with advanced colorectal cancer--results from a non-interventional observation study.
Stein A; Quidde J; Schröder JK; Göhler T; Tschechne B; Valdix AR; Höffkes HG; Schirrmacher-Memmel S; Wohlfarth T; Hinke A; Engelen A; Arnold D
BMC Cancer; 2016 Feb; 16():82. PubMed ID: 26865161
[TBL] [Abstract][Full Text] [Related]
16. Health-related quality of life in early breast cancer.
Groenvold M
Dan Med Bull; 2010 Sep; 57(9):B4184. PubMed ID: 20816024
[TBL] [Abstract][Full Text] [Related]
17. Single-agent capecitabine in patients with metastatic colorectal cancer refractory to 5-fluorouracil/leucovorin chemotherapy.
Lee JJ; Kim TM; Yu SJ; Kim DW; Joh YH; Oh DY; Kwon JH; Kim TY; Heo DS; Bang YJ; Kim NK
Jpn J Clin Oncol; 2004 Jul; 34(7):400-4. PubMed ID: 15342667
[TBL] [Abstract][Full Text] [Related]
18. Effectiveness of a home care nursing program in the symptom management of patients with colorectal and breast cancer receiving oral chemotherapy: a randomized, controlled trial.
Molassiotis A; Brearley S; Saunders M; Craven O; Wardley A; Farrell C; Swindell R; Todd C; Luker K
J Clin Oncol; 2009 Dec; 27(36):6191-8. PubMed ID: 19917849
[TBL] [Abstract][Full Text] [Related]
19. Characterization of Durable Responder for Capecitabine Monotherapy in Patients With Anthracycline- and Taxane-Pretreated Metastatic Breast Cancer.
Hong JY; Park YH; Choi MK; Jung HA; Lee SJ; Ahn JS; Im YH
Clin Breast Cancer; 2015 Oct; 15(5):e287-92. PubMed ID: 25997855
[TBL] [Abstract][Full Text] [Related]
20. Adherence and patients' experiences with the use of oral anticancer agents.
Timmers L; Boons CC; Kropff F; van de Ven PM; Swart EL; Smit EF; Zweegman S; Kroep JR; Timmer-Bonte JN; Boven E; Hugtenburg JG
Acta Oncol; 2014 Feb; 53(2):259-67. PubMed ID: 24266637
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
